Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company

GALWAY, IRELAND--December 2, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical major Novartis International AG (NYSE:NVS) (Basel, Switzerland) is betting big on heart drug prospect inclisiran with a 8.8 billion euro ($9.7 billion) takeover of The Medicines Company (NASDAQ: MDCO) (New Jersey). Within this article: Details takeover, drugs involved, rivals and market opportunity

Subscribe Now!

(All Fields Required)

Fill Out Form To Subscribe +

First Name

Last Name

Email Address

Username

Password

Repeat Password

All Members Receive the Following Resources:

Industry News Digest
Upcoming Podcasts
On-Demand Podcasts
Economic Indicators

View All Member Resources

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

For More Info!

Industrial Info Resources

Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company

Login or Register for Instant Access

Subscribe Now!

Related Articles

All Members Receive the Following Resources: